Related Experiment Video
Updated: Jun 17, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges
1Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
Abstract:
Glioblastoma, a highly malignant intracranial tumor, has acquired slow progress in treatment. Previous clinical trials involving targeted therapy and immune checkpoint inhibitors have shown no significant benefits in treating glioblastoma. This ineffectiveness is largely due to the complex immunosuppressive environment of glioblastoma. Glioblastoma cells exhibit low immunogenicity and strong heterogeneity and the immune microenvironment is replete with inhibitory cytokines, numerous immunosuppressive cells, and insufficient effective T cells. Fortunately, recent Phase I clinical trials of CART therapy for glioblastoma have confirmed its safety, with a small subset of patients achieving survival benefits. However, CART therapy continues to face challenges, including blood-brain barrier obstruction, antigen loss, and an immunosuppressive tumor microenvironment (TME). This article provides a detailed examination of glioblastoma's immune microenvironment, both from intrinsic and extrinsic tumor cell factors, reviews current clinical and basic research on multi-targets CART treatment, and concludes by outlining the key challenges in using CART cells for glioblastoma therapy.
Insights
CAR T-cell therapy shows promise for glioblastoma treatment, demonstrating safety and survival benefits in early trials. Overcoming challenges like the immunosuppressive tumor microenvironment is key for broader efficacy.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Biology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- Previous therapies, including targeted treatments and immune checkpoint inhibitors, have shown minimal efficacy due to GBM's immunosuppressive tumor microenvironment (TME).
- The GBM TME is characterized by low tumor cell immunogenicity, heterogeneity, immunosuppressive cytokines, and a lack of effective T cells.
Purpose of the Study:
- To examine the complex immune microenvironment of glioblastoma.
- To review current research on multi-target CAR T-cell therapy for glioblastoma.
- To identify key challenges hindering CAR T-cell efficacy in glioblastoma treatment.
Main Methods:
- Review of existing clinical trials and basic research on CAR T-cell therapy for glioblastoma.
- Analysis of glioblastoma's intrinsic and extrinsic tumor cell factors contributing to its immune microenvironment.
- Evaluation of challenges associated with CAR T-cell therapy, including blood-brain barrier penetration and antigen loss.
Main Results:
- Phase I clinical trials indicate CAR T-cell therapy is safe for glioblastoma patients.
- A subset of patients experienced survival benefits from CAR T-cell therapy.
- Significant challenges remain, including overcoming the blood-brain barrier, addressing antigen loss, and mitigating the immunosuppressive TME.
Conclusions:
- CAR T-cell therapy presents a potential new avenue for glioblastoma treatment, with initial safety and efficacy demonstrated.
- Addressing the multifaceted immunosuppressive tumor microenvironment is critical for enhancing CAR T-cell therapy outcomes.
- Further research and development are necessary to overcome existing obstacles and optimize multi-target CAR T-cell strategies for glioblastoma.
